Compare Roundhill Magnificent Seven ETF (MAGS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novartis AG — how do they compare? Roundhill Magnificent Seven ETF trades at $73.39 (market cap $5.78B), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 46.5× Roundhill Magnificent Seven ETF's market cap, and Novartis AG pays a 3.31% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Novartis AG for 82 Days on average.
| MAGS | NVS | |
|---|---|---|
Market Cap | $5.78B | $268.57B |
Volume | 4,410,665 | 1,532,573 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $168.62 |
52-Week Low | $55.39 | $121.80 |
Typical Hold Time | 36 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the S&P 500 in 2026 with only 2% YTD gains. Recent news highlights AI-driven momentum from holdings like Meta and NVIDIA, but also notes the Magnificent Seven theme showing signs of fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but concentration risk and valuation concerns persist. Key opportunities include pure-play exposure to AI growth engines, while risks involve market rotation away from mega-caps and aggressive capital expenditure cycles impacting shareholder returns. Technical support sits at $73 with resistance at $74-75.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
